JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

A REVIEW ON MULTI-DRUG RESISTANCE TUBERCULOSIS

Name Of First Author- Arati Subhash Avhad

Designation Of First Author- Student

Name Of Department Of First Autor- B Pharmacy

Name Of Organization Of First Author- Pravara Rural Education

Society College Of Pharmacy (For Women's) Chincholi , Nashik.

City – Nashik , Country – India.

Name Of Second Author- Mr. Rahul. D. Khaire

Designation Of Second Author- Staff (M.Pharm)

(Department Of Pharmaceutical Chemistry)

Abstract : Multi drug resistant means the resistance produce by isoniazid and rifampicin with or without resistance to other drugs like most of the anxious element of a pandemic of Antibiotic Resistance. Multi drug resistant tuberculosis caused by the mycobacterium tuberculosis and in rare cases mycobacterium bovis. Mycobacterium bovis is present in the unpasteurized cow milk. Mycobacterium tuberculosis is spread through the air from person to person while sneezing , talking , droplet inhalation , inadequate health care, living in crowded area ,health care workers, malnutrition. Multi drug resistant tuberculosis [MDR-TB] is not easily cure. It is difficult to cure when proper treatment are taken. Improper treatment and poor treatment led to multi drug resistance tuberculosis. Proper management and therapy of tuberculosis particularly drug resistant tb by professional and expert physician ,special diagnosis by test , innovation of new Anti-tubercular drug [molecule],vaccines and knowing the real magnitude of MDR-TB are some important problem for productive prevent and management of MDR-TB. The main causes of the spread of resistant TB are weak medical systems, amplification of resistance pattern through incorrect treatment and transmission in communities and facilities. Some strains of tuberculosis are resistant to first or second line drug treatments. Their continuing spread is one of the most urgent challenges facing global TB control.

IndexTerms - Multi- drug resistance tuberculosis, Transmission , Diagnosis , Treatment

INTRODUCTION-

Multidrug resistance tuberculosis is due to an organism this is proof against as a minimum isoniazid and rifampin, the 2 maximum strong TB drugs. Tuberculosis is due to Mycobacterium Tuberculosis and in uncommon instances Mycobacterium Bovis . mycobacterium bovis is found in unpasteurized cow milk . Mycobacterium tuberculosis is unfold through the air from man or woman to in keeping with-son whilst sneezing , talking , droplet inhalation , insufficient fitness care, residing in crowded area ,fitness care workers, malnutrition. 1.7 million human beings deaths yearly from TB and tb is the second one main infectious killer after COVID-19. Misuse of the isoniazid and rifampicin has led to emergence of the multidrug resistance tb and considerably drug resistance tb. Extensively drug resistance tb are the resistance to isoniazid and rifampicin and similarly of any fluroquinolone , and as a minimum one of the 3 injectable drugs; capreomycin, kanamycin, amikacin .The U.S. reviews 90-one hundred instances in keeping with yr

of MDR-TB. It calls for extended treatment period can also additionally cause toxicity of medicine and better cost . The motives for why multidrug resistance keeps to unfold are mistreatment of TB and man or woman to man or woman trans-mission . The period of remedy for MDR-TB is 24-27 months and the drug are utilized in remedy are kanamycin , levofloxacin , cycloserin, ethionamide, pyrazinamide and ethambutol. Adverse drug response which for multi drug resistance tb remedy can reason substantial long time morbidity.[1,2]

EPIDERMIOLOGY-

Even aleven though tuberculosis [TB] is a treatable infectious disorder , an anticipated 1.three million people died from TB in 2012 [WHO 2013 a] . One of the predominant motives is that TB keeps to adapt resistance to drugs.[3] Today the persevering with the unfold of MDR TB is one of the maximum pressing and hard demanding situations are dealing with worldwide TB manipulate. In 2012 , there have been ap-prox. four,50,000 new instances of MDR TB and 1,70,000 deaths . Globally , MDR TB is found in 3.8% of recent TB affected person and 20% of sufferers who've a records of preceding treatment . The maximum MDR quotes are located in nations of Eastern Europe and Central Asia[4].In 2012 , the china facilities for disorder manipulate and prevention pronounced that 10% of china's 1.four million TB sufferers had MDR-TB . MDR is a developing hassle in South Africa[5].

TRANSMISSION -

Tuberculosis is a contagious disorder which can be unfold in touch with TB patient .The TB is frequently transmitted via the inhalation of breathing droplet containing MDR TB bacteria eject [remove] via way of means of individual [specific person] with lively MDR TB . inclusive of drug touchy TB, near and extended touch with a transmitted character is the primary mode of the unfold of a disorder .protection degree like right diagnosis , remedy in addition to contamination manage practices are essential to lower the charge unfold of MDR-TB.[6]

PRIMARY MDR TB TRANSMISSION-

Resistance to antibiotic first seems whilst sufferers with drug -susceptible [DS] TB go through insufficient both interrupted therapy ,set off to the choice of drug resistant micro organism as properly as 'Acquired drug resistance'[7]. However,as soon as resistant micro organism have come to be pick out in an infectious patient, they will then transmit to others via airborne droplets as 'primary' or transmitted drug resistance[8].

DIAGNOSIS OF MDR TB-

LABORATORY DIAGNOSIS OF MDR-TB AND XDR-TB-

Early desire of suitable treatement is an critical determinant of beneficial outcome, and speedy willpower of drug resistance can permit a custom designed technique to treat. Early withinside the direction of ailment and might probably lessen morbidity, mortality and infections.[9]

New drug and techniques for treating drug resistance tuberculosis

Developing new routine for drug resistance tuberculosis is challenging. Tuberculosis capsules paintings in mixture and an powerful routine need to consist of at the least one drug with strong bactericidal interest to hastily lessen mycobacterial burden. This position is stuffed with the aid of using isoniazid in drug-prone tuberculosis. Drugs with strong sterilizing interest [eg. Rifampicin and pyra-zinamide in drug susceptible tb] , which correctly kill semidormant , persisting organism so that it will purpose relapse.

Successful prognosis and remedy of MDR-TB are primarily based totally on a speedy and particular drug sensi-tivity test (DST), which presents proof for choosing an powerful drug.[10]]. DST is di-vided into phenotypic exams that look at boom or metabolic inhibition in anti-TB drug-unfastened and drug-containing media and molecular exams that locate genes associated with drug resistance [11]

Conventional phenotypic DST is a stable subculture-primarily based totally technique that makes use of egg-primarily based totally or agar-primarily based totally media. There are 3 exclusive methods, namely: the share technique, the resistance ratio technique, and absolutely the awareness technique [12,13]. The percentage technique is the maximum normally used technique. It is the reference technique for phenotypic testing, which presents a degree of the susceptibility of the micro organism to a drug [13,14]. The absolute concentration technique is likewise normally used because of its technical convenience [11]. These meth-ods are sensitive, have suitable scientific correlation, and permit the willpower of minimum inhibitory awareness. However, it takes a fantastically long term so long as 2 to a few months to verify the DST outcomes because of the lengthy turnaround time for MTB subculture[15]. Liquid subculture and DST have a better fee of MTB isolation and require much less time for detection than stable subculture and DST. However, it's far greater steeply-priced and incorporates a threat of accelerated bacterial con-tamination and go contamination with the aid of using nontuberculous mycobacterial isolation[16]. Among the liquid-primarily based totally subculture structures, the maximum normally used structures are BACTEC 460 that detects carbon dioxide manufacturing and MGIT that detects oxygen consumption[16] Molecular DSTs had been evolved to provide a bonus

over traditional phenotypic exams which are greater time-consuming. These assessments may be used to diagnose TB via amplification of nucleic acids. They stumble on drug resistance with the aid of using figuring out genetic mutations in particular genes. These genotypic assessments are extra speedy and correct than the phenotypic DSTs[13] .Molecular DSTs are divided extensively into types; probe-primarily based totally assays and series-primarily based totally assays. The probe-primarily based totally DSTs consist of line probe assays (LPA) and GeneXpert (Cepheid Inc., Sunnyvale, CA, USA). In 2008, WHO accepted using industrial LPAs (the INNO-LiPA Rif.TB assay [Innogenetics, Ghent, Belgium] and the GenoType MTBDRplus model 1 [MTBDRplus; Hain Lifescience GmbH, Nehren, Germany]) for detecting MTB and drug re-sistance[18] In 2015, WHO carried out a systemic assessment of the accuracy of industrial LPAs (MTBDRplus model 1, model 2, and Nipro NTM+MTBDR [NIPRO Corp., Osaka, Japan]) for detecting MTB and resistance to isoniazid and rifampicin, and later in 2016, WHO endorsed using LPAs in sufferers with way of life-high quality (direct testing) or a sputum smear-high quality specimens (oblique testing)[19,20]. Although MTBDR plus has proven excessive accuracy for rifampicin resistance (98.7%), its accuracy for isoniazid is variable and has noticeably low sensitivity (84.3%) [21]. Recently, the WHO endorsed the GenoType MTBDRsl (Hain Lifescience GmbH) that changed into advanced to stumble on resistance to ethambutol (mutation in embB), fluoroquinolones (mutations in gyrA and gyrB), and injectable agents (mutation in rrs, main to resistance to kanamycin, amikacin, and capreomycin) [22].
In 2020, the up to date WHO tips endorsed using molecular assays (Xpert MTB/RIF and Xpert MTB/RIF [Xpert Ultra]; GeneXpert) because the preliminary check for the analysis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children [20,23]. The Xpert MTB/RIF is a completely automatic real-time PCR primarily based totally molecular assay for detecting MTB and resistance to rifampicin [24], which gives consequences inside 2 hours. In a huge clini-cal trial, the Xpert MTB/RIF confirmed an MTB detection accuracy of 98.2% in smear-high quality and way of life-high quality sufferers, however the accuracy changed into 72.5% in smear-bad and way of life-high quality sufferers. The specificity of the Xpert MTB/RIF changed into 99.2%. In the equal have a look at, the Xpert MTB/RIF confirmed 97.6% sensitivity for detecting rifampicin resistance [19]. The WHO additionally recommends Xpert MTB/RIF for the analysis of extrapulmonary TB (e.g., tuberculous lymphadenitis and tuberculous meningitis) primarily based totally on a scientific assessment [25]. The Xpert Ultra changed into advanced to enhance the sensitivity of TB analysis (in particular in smear-bad, hu-guy immunodeficiency virus [HIV]-inflamed sufferers and in case of extrapulmonary TB together with tuberculous meningitis and tuberculous lymphadenitis) and rifampicin resistance identifica-tion. For TB detection, the sensitivity of Xpert Ultra changed into better than that of Xpert in smear-bad sufferers and in sufferers with HIV, however the specificity changed into decrease than that of Xpert in all sufferers [26]. A latest have a look at pronounced that Xpert Ultra changed into now no longer advanced to Xpert in diag-nosing tuberculous meningitis [25].
Probe-primarily based totally DSTs aren't capable of stumble on resistance profiles whilst mutations arise out of doors the goal genetic region [27]. Next-era sequencing (NGS) is a method that could compen-sate for this weakness. NGS gives speedy and certain series facts of part of the genome (focused NGS) or the entire genome (entire genome sequencing). It can perceive genotypes that expect drug-resistant phenotypes. It also can offer genetic facts that could stumble on transmission in capability outbreak situation [28] This method can offer drug susceptibility profiles now no longer handiest for the first-line pills however additionally for plenty second-line pills [29]. However, NGS has numerous disadvantages, together with terrible sensitivity even as the usage of sputum in preference to way of life isolate as a specimen and the want for specialised staff [30].

MECHANISM OF MULTI DRUG RESISTANCE

Drug resistance to Mycobacterium tuberculosis (MTB) effects from spontaneous and random chromosomal mutations that bring about decreased susceptibility to unique agents [31]. The mechanism main to the improvement of drug resistance consists of activation of the efflux pump on the floor of the bacteria, drug goal alteration, manufacturing of drug inactivating enzymes, and disruption of drug activation [11]. The occurrence of MDR-TB is low, because the fee of mutation is 10−five for isoniazid and 10−7 for rifampicin [32]. Drug resistance can arise in ways (number one or secondary resistance). Primary resistance develops whilst sufferers are uncovered to and inflamed with an already drug-resistant strain. Secondary resistance or received resistance develops because of terrible adherence to medication, drug malabsorption, and insufficient routine amongst sufferers taking TB medication. Although maximum instances of MDR-TB stand up from received resistance, a preceding take a look at stated that maximum of the incidences of MDR-TB resulted from transmission as opposed to acquisition of resistance at some point of remedy in maximum high-burden settings [33].

TREATMENT OF MULTI- DRUG RESISTANCE

The purpose of remedy for MDR-TB is to treatment the man or woman affected person and to keep away from the transmission of MDR-TB to different people. The WHO advanced suggestions for the programmatic management of drug-resistant TB in 2006 and up to date those suggestions in 2011. These up to date suggestions suggest the usage of fast prognosis of rifampicin resistance and a mixture of 4 powerful tablets, inclusive of pyrazinamide, an injectable agent, and a later technology fluoroquinolone for the remedy of sufferers with MDR-TB[34]. In the up to date suggestions of 2016, the WHO recommended MDR-TB regimens with as a minimum 5 powerful TB tablets, inclusive

of pyrazinamide and 4 second-line TB tablets [35]. Drugs to be blanketed within side the routine are fluoroquinolone, an injectable agent, ethionamide or prothionamide, pyrazinamide, and both cycloserine or para-aminosalicylic acid . Rapid DST for isoniazid and rifampicin or rifampicin by myself is advocated. The WHO launched a fast communique in 2018 [36]. and up to date the consolidated suggestions in 2019 [37]. These suggestions encompass a brand new drug classification, suggestions for constructing regimens, more suitable tracking strategies, and a viable implementa-tion plan primarily based totally on scientific trials and man or woman affected person facts meta-evaluation (IPD-MA)[37,38,39]. A current IPD-MA inclusive of 12,030 sufferers from 25 international locations worried evaluation of anti-MDR-TB tablets related to favorable outcomes. Treatment fulfillment changed into definitely related to the usage of linezolid, levofloxacin, carbapenems, moxifloxacin, be-daquiline, and clofazimine. Reduced mortality changed into considerably related to the usage of linezolid, levofloxacin, moxifloxacin, and bedaquiline. Streptomycin and amikacin supplied modest advantages whilst as compared with regimens with out injectable agents. Oral regimens are favored for nearly all sufferers. Fluoroquinolones (levofloxacin or moxifloxacin), bedaqui-line, and linezolid are strongly advocated for an extended MDR-TB routine. These 3 tablets ought to be blanketed withinside the preliminary remedy until there's an proof of drug resistance or a danger of toxicity. In IPD-MA, whilst as compared with injectable-loose routine, routine includ-ing streptomycin or amikacin changed into related to multiplied remedy fulfillment, whilst routine inclusive of kanamycin or capreomycin confirmed poorer outcomes. Kanamycin remedy changed into as-sociated with decrease remedy fulfillment, and capreomycin changed into related to decrease fulfillment and better mortality[38].

1.CLASSIFICATION OF DRUG –

In 2018, the WHO fast communique labeled the medication for the longer MDR-TB routine into 3 groups[36]. Agents in institution A consist of **fluoroquinolones, bedaquiline, and linezolid,** which might be fairly powerful and strongly advocated withinside the MDR-TB routine except contra-indicated. **Clofazimine** and both **cycloserine or terizidone** are protected in institution B. These capsules are conditionally advocated as the second one choice. Group C capsules like **ethambutol,delamanid,pyrazinamide,meropenem,amikacin or ethionamide** may be used whilst an adequate routine can not be formulated with retailers from institution A or institution B. Agents in institution C are ranked via way of means of the stability of advantages to toxicities. It consists of all different capsules besides high-dose isoniazid, amoxicillin-clavulanate, kanamycin, and capreomycin.

Fluoroquinolones are powerful in opposition to developing in addition to non-developing tuberculous bacilli and are properly tolerated over the lengthy remedy period. Fluoroquinolones inhibit DNA transcription and bacterial replication of MTB via way of means of interfering with DNA gyrase, that is a tetramer com-posed of α and β subunits encoded via way of means of gyrA and gyrB genes[40]. **Levofloxacin and moxifloxacin** are the 2 maximum regularly advocated retailers, and the WHO has recom-mended the usage of those capsules for the remedy of MDR-TB. The premiere dose of levofloxa-cin is 750 mg as soon as every day and that of moxifloxacin is four hundred mg as soon as every day. The examine from South Korea stated that levofloxacin and moxifloxacin have comparable effectiveness and aspect consequences[41]. Adverse consequences of fluoroquinolones consist of gastrointestinal trouble, issues associated with the principal frightened system, and QT c language prolongation. However everlasting discontinuation of fluoroquinolones because of aspect consequences changed into uncommon[42]. Linezolid is an oxa-zolidinone antibiotic that inhibits bacterial protein synthesis via way of means of stopping the fusion of 30S and 50S ribosomal subunits[43]. In 2018, withinside the fast communique launched via way of means of the WHO concerning remedy of MDR-TB, linezolid changed into in addition accelerated to institution A. The effectiveness of **linezolid** withinside the remedy of drug-resistant TB has been showed in scientific trial and meta-analysis [38,43].

Bedaquiline is a diarylquinoline compound that in particular inhibits the adenosine triphosphate synthase via way of means of blocking off the float of mycobacterial proton pump[44]. Bedaquiline has a concentration-based bactericidal impact via way of means of inflicting mobileular demise in each replicating and non-replicating mycobacteria[45]. Bedaquiline is properly absorbed, and its absorption will increase with food. According to the scientific facts for safety, tolerability, and efficacy, the U.S. Food and Drug Administration authorized the dose of four hundred mg every day for 14 days observed via way of means of 2 hundred mg 3 instances weekly for 22 weeks [46]. **Delamanid** is a brand new anti-TB agent derived from the nitro-dihydro-imidazooxazole magnificence of compounds that inhibits mycolic acid synthesis of bac-terial mobileular wall. It has proven amazing in vitro and in vivo hobby in opposition to each drug-prone and drug-resistant lines of MTB in early scientific development[47,48]. However, numerous research stated that delamanid-containing routine changed into as powerful and secure as bedaquiline[49,50].

DURATION OF TREATMENT

The most advantageous period of remedy for MDR-TB is unclear. The WHO recommends styles of standardized MDR-TB remedy regimens (longer and shorter regimens) [37]. They range in drug aggregate in addition to in period. Treatment with the longer routine is usually recommended for 18 to twenty months (at the least 15 to 17 months after subculture conversion), and oral regimens are pre-ferred. The in depth section, which lasts for six to 7 months and consists of at the least 4 drugs, is usually recommended till bedaquiline is stopped. The endorsed period of remedy can

be changed relying at the subculture conversion popularity and the patient's reaction to remedy [37]. The continuation section of the remedy need to consist of at the least 3 drugs[37] ATS/CDC/ERS/IDSA hints endorsed the period of in depth section to be be-tween five and seven months after subculture conversion [42]. The endorsed period of brief duration routine is nine to eleven months. The brief routine may be an opportunity to the longer regi-guys in easy MDR-TB instances beneathneath precise conditions. This routine consists of an in depth section lasting four to six months, which incorporates seven drugs (kanamycin, moxifloxacin, prothion-amide, clofazimine, pyrazinamide, high-dose isoniazid, and ethambutol). It is accompanied through a five-month direction with moxifloxacin, clofazimine, pyrazinamide, and ethambutol. Exclusion standards for the shorter routine are (1) resistance to or suspected ineffectiveness of a remedy from the shorter routine (besides isoniazid resistance); (2) publicity to at least one or extra second-line drugs from the shorter MDR-TB routine for more than 1 month; (3) intolerance to drugs from the shorter MDR-TB routine or chance of toxicity (e.g., drug-drug interactions); (four) pregnancy; (five) disseminated, meningeal, or principal fearful gadget TB; (6) any extrap-ulmonary ailment in sufferers with HIV infection; and (7) unavailability of at the least one medi-cine from the shorter MDR-TB routine. ATS/CDC/ERS/IDSA did now no longer make a recommenda-tion both for or towards the standardized brief-direction routine[42].

AKNOWLEGEMENT –

I would like to thank my guide teacher Mr. Rahul. D. Khaire and other staff members of my institution pravara college of pharmacy chincholi, (Nashik). Special thanks give to my guide teacher khaire sir give time to time guidance for successful completion of my review article.

REFERENCES –

1. S.M. Marks, J. Flood, B. Seaworth, Y. Hirsch-Moverman, L. Armstrong, S. Mase, *et al.* Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007 Emerg Infect Dis, 20 (2014), pp. 812-821
2. Curry International Tuberculosis Center and California Department of Public Health Drug-resistant tuberculosis: a survival guide for clinicians (3rd ed.) (2016)
3. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona J, Becerra M, Benedetti A, Burgos M, Centis R, et al. 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients. *PLoS Med* 9: e1001300.
4. Becerra M, Franke MF, Appleton SC, Joseph JK, Bayona J, Atwood SS, Mitnick CD. 2013. Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. *Pediatr Infect Dis J* 32: 115–119.
5. Cegielski JP. 2010. Extensively drug-resistant tuberculosis: "There must be some kind of way out of here". *Clin Infect Dis* 50: S195–S200.
6. www.chatgpt.com
7. K.J. Seung, I.E. Gelmanova, G.G. Peremitin, V.T. Golubchikova, V.E. Pavlova, O.B. Sirotkina, *et al.*

   The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis
   Clin Infect Dis, 39 (2004), pp. 1321-1328
8. S. Borrell, S. Gagneux Infectiousness, reproductive fitness and evolution of drug-resistant mycobacterium tuberculosis Int J Tuberc Lung Dis, 13 (2009), pp. 1456-1466
9. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. *Lancet Infect Dis.* 2006;6:710–25.

10. World Health Organization . Geneva: World Health Organization; 2019. Global tuberculosis report 2019 [Internet] [cited 2020 July
11. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. *Eur Respir J.* 2005;25:564–9.
12. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. *Bull World Health Organ.* 1963;29:565–78.
13. World Health Oraganization . 4th ed. Geneva: World Health Oraganization; 2009. Guidelines for surveillance of drug resistance in tuberculosis [Internet] [cited 2020 Jul 14.
14. CanettI G, Rist N, Grosset J. Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation. *Rev Tuberc Pneumol (Paris)* 1963;27:217–72.
15. Schaberg T, Reichert B, Schülin T, Lode H, Mauch H. Rapid drug susceptibility testing of Mycobacterium tuberculosis using conventional solid media. *Eur Respir J.* 1995;8:1688–93.
16. World Health Organization . Geneva: World Health Organization; 2007. Use of liquid TB culture and drug susceptibility testing (DST) in low and medium income setting. Summary report of the Expert Group Meeting on the use of liquid culture media [Internet] [cited 2018 Dec 18].
17. Coll F, McNerney R, Preston MD, Guerra-Assunção JA, Warry A, Hill-Cawthorne G, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. *Genome Med.* 2015;7:51.
18. World Health Organization . Geneva: World Health Organization; 2008. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB) [Internet] [cited 2020 Jul 14].
19. World Health Organization . Geneva: World Health Organization; 2016. The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin [Internet] [cited 2020 Jul 14].
20. World Health Organization . Geneva: World Health Organization; 2020. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis–rapid diagnostics for tuberculosis detection [Internet] [cited 2020 Jul 14].
21. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. *Eur Respir J.* 2008;32:1165–74.
22. Theron G, Peter J, Richardson M, Barnard M, Donegan S, Warren R, et al. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. *Cochrane Database Syst Rev.* 2014;(10):CD010705.
23. World Health Organization . Geneva: World Health Organization; 2020. Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: rapid communication [Internet] [cited 2020 Jun 5].
24. El-Hajj HH, Marras SA, Tyagi S, Kramer FR, Alland D. Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons. *J Clin Microbiol.* 2001;39:4131–7.
25. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. *Eur Respir J.* 2014;44:435–46.
26. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. *Lancet Infect Dis.* 2018;18:76–84.

27. Feliciano CS, Namburete EI, Rodrigues Plaça J, Peronni K, Dippenaar A, Warren RM, et al. Accuracy of whole genome sequencing versus phenotypic (MGIT) and commercial molecular tests for detection of drug-resistant Mycobacterium tuberculosis isolated from patients in Brazil and Mozambique. *Tuberculosis (Edinb)* 2018;110:59–67.
28. Witney AA, Cosgrove CA, Arnold A, Hinds J, Stoker NG, Butcher PD. Clinical use of whole genome sequencing for Mycobacterium tuberculosis. *BMC Med.* 2016;14:46.
29. Witney AA, Cosgrove CA, Arnold A, Hinds J, Stoker NG, Butcher PD. Clinical use of whole genome sequencing for Mycobacterium tuberculosis. *BMC Med.* 2016;14:46.
30. World Health Organization . Geneva: World Health Organization; 2018. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide [Internet] [cited 2020 Jul 14].
31. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. *Appl Microbiol.* 1970;20:810–4.
32. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. *Int J Tuberc Lung Dis.* 2015;19:1276–89.
33. Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. *Lancet Respir Med.* 2015;3:963–72.
34. World Health Organization . Geneva: World Health Organization; 2011. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update [Internet] [cited 2020 Jul 14].
35. World Health Organization . Geneva: World Health Organization; 2016. Treatment guidelines for drug-resistant tuberculosis, 2016 update [Internet] [cited 2020 Jul 14].
36. World Health Organization . Geneva: World Health Organization; 2011. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) [Internet] [cited 2020 Jul 14].
37. World Health Organization . Geneva: World Health Organization; 2019. WHO consolidated guidelines on drug-resistant tuberculosis treatment [Internet] [cited 2020 Jul 14].
38. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. *Lancet.* 2018;392:821–34.
39. Bastos ML, Lan Z, Menzies D. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. *Eur Respir J.* 2017;49:1600803.
40. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. *Drugs.* 2007;67:2077–99.
41. Kang YA, Shim TS, Koh WJ, Lee SH, Lee CH, Choi JC, et al. Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. *Ann Am Thorac Soc.* 2016;13:364–70.
42. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. *Am J Respir Crit Care Med.* 2019;200:e93–142.
43. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. *J Antimicrob Chemother.* 2013;51(Suppl 2):ii9–16.

44. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. *Nat Chem Biol.* 2007;3:323–4.
45. Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. *Antimicrob Agents Chemother.* 2012;56:1444–51.
46. Centers for Disease Control and Prevention Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. *MMWR Recomm Rep.* 2013;62(RR-09):1–12.
47. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. *PLoS Med.* 2006;3:e466.
48. Barry PJ, O'Connor TM. Novel agents in the management of Mycobacterium tuberculosis disease. *Curr Med Chem.* 2007;14:2000–8.
49. Kim CT, Kim TO, Shin HJ, Ko YC, Choe YH, Kim HR, et al. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea. *Eur Respir J.* 2018;51:1702467.
50. Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. *Lancet Infect Dis.* 2018;18:536–44.